Company overview

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from replicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. CDI  Bioscience, Inc. also offers  CHO cell lines preengineered with RP Shift® technology (PACE™ cell lines).

Our mission

Recombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge. CDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI’s core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.